Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2022 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
Whether the third quarterly financial statements are audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Date and Financial Indicators
Unit: Yuan Currency: RMB
From the
beginning of the
For the Reporting
Item YoY change (%) year to the end of YoY change (%)
Period
the Reporting
Period
Revenue 4,447,021,452.61 8.51 13,011,966,738.16 9.04
1 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Net profit attributable to
shareholders of the listed 325,293,433.73 1.23 1,126,561,953.23 11.69
company
Net profit attributable to
shareholders of the listed
312,360,089.27 -2.90 1,116,354,521.30 21.40
company after deduction of
extraordinary gains and losses
Net cash flow from operating
N/A N/A 2,608,992,532.97 60.93
activities
Basic earnings per share
0.1748 6.61 0.5983 16.09
(RMB/share)
Diluted earnings per share
0.1739 6.19 0.5971 16.13
(RMB/share)
Weighted average return on Decreased by 0.11 Increased by 0.50
2.74 9.39
net assets (%) percentage points percentage points
As at the end of the
As at the end of the previous year YoY change (%)
Reporting Period
Total assets 34,713,695,364.54 31,103,900,389.29 11.61
Owner's equity attributable to
shareholders of the listed 12,900,492,209.56 11,820,293,656.69 9.14
company
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this quarter,
the same below.
2. From July to September 2022, the Company realized net profit attributable to shareholders of the
parent of RMB325 million, of which Joincare excluding Livzon Pharmaceutical Group Inc. (“Livzon Group”)
and Livzon MAB Pharm Inc. (“Livzon MAB”) realized net profit attributable to shareholders of the parent of
approximately RMB217 million, representing a YoY increase of approximately 37%, and the impact of Livzon
MAB on the net profit attributable to shareholders of the parent was approximately negative RMB186 million.
From January to September 2022, the Company realized net profit attributable to shareholders of the parent of
RMB1,127 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit
attributable to shareholders of the parent of approximately RMB638 million, representing a YoY increase of
approximately 42%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent
was approximately negative RMB325 million.
3. From January to September 2022, the Company realized revenue of RMB7,402 million from
chemical pharmaceuticals, representing a YoY increase of 7.16%, among which, RMB862 million were from
respiratory formulation, representing a YoY increase of 215%; RMB1,151 million were from anti-infective
products, representing a YoY increase of 9.29%; RMB2,646 million were from gastroenterology products,
representing a YoY decrease of 11.60%; RMB2,092 million were from gonadotropic hormones, representing a
YoY increase of 5.81% and RMB400 million were from psychiatry products, representing a YoY increase of
30.68%. The Company realized revenue of RMB4,054 million from APIs and intermediates, representing a
YoY increase of 17.80%. The Company realized revenue of RMB864 million from traditional Chinese
medicine, representing a YoY increase of 1.28%. The Company realized revenue of RMB502 million from
diagnostic reagents and equipment, representing a YoY decrease of 9.09%. The Company realized revenue of
RMB83 million from health care products, representing a YoY decrease of 4.30%.
2 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
From the beginning of the
For the Reporting
Item year to the end of the
Period
Reporting Period
Gain or loss on disposal of non-current assets 1,429,336.99 5,161,222.54
Government grants recognized in profit or loss for the current
period (excluding government grants that are closely related to
the ordinary operating business of the Company and are 45,982,790.93 140,167,993.52
provided in fixed amount or quantity continuously according to
the applicable polices and standards of the country)
Gains and losses on fair value changes incurred from financial
assets held for trading, derivative financial assets, financial
liabilities held for trading and derivative financial liabilities, and
investment income on disposal of financial assets held for
-14,007,798.34 -112,944,327.05
trading, derivative financial assets, financial liabilities held for
trading, derivative financial liabilities and other debt
investments, except for effective hedging activities related to the
ordinary operating business of the Company
Reversal of provision for impairment of accounts receivable and
0.00 158,470.77
contract assets tested for impairment individually
Other non-operating income and expenses apart from the above
-6,269,628.08 -8,540,320.05
items
Less: Effect of income tax -330,154.62 10,109,361.17
Effect of minority equity (after tax) 14,531,511.66 3,686,246.63
Total 12,933,344.46 10,207,431.93
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory
Announcement No. 1 for Public Company Information Disclosures –Non-recurring Profits and Losses as
items of recurring profit or loss
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Therefor
√Applicable □N/A
Item Change (%) Main reasons
Net cash flow from Mainly due to an increase of cash
60.93
operating activities collections of sales revenues.
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons
Therefor
3 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Change in
30 September 31 December
Balance Sheet proportion Main Reason
2022 2021
（%）
Primarily due to fluctuations in
Financial assets held
121,394,233.59 184,638,344.31 -34.25 market value of the securities
for trading
investment held.
Mainly due to the receipt of
Other receivables 51,182,462.61 88,053,825.12 -41.87 payment during the current
period.
Non-current assets due Primarily due to the recovery of
38,498.84 317,381.23 -87.87
within one year finance lease payments.
Primarily due to the decrease in
the amount of VAT credits as a
Other current assets 28,941,853.23 83,986,214.37 -65.54 result of the refund thereof and
the prepaid income tax has
transferred out.
Primarily due to the recovery of
Long-term receivables 82,574.69 266,904.13 -69.06
finance lease payments.
Primarily due to fluctuations in
Financial liabilities
23,888,725.35 143,302.24 16570.17 fair value of foreign exchange
held for trading
forward contract
Primarily due to some contract
performance obligations during
the current period, which
Contract liabilities 85,390,395.48 234,140,702.29 -63.53 satisfies the conditions for
revenue recognition and results
in the carrying forward of
revenue.
Primarily due to the increase in
Taxes payable 356,093,489.85 270,618,183.41 31.59
corporate income tax payable.
Mainly due to an increase of
Non-current liabilities
19,385,099.93 91,576,066.33 -78.83 repayment of long-term
due within one year
borrowings.
Primarily due to the decrease in
pending output tax as the
contract payment collected in
Other current liabilities 5,977,716.75 15,626,224.29 -61.75
advance in the current period
meets the revenue recognition
conditions and is carried forward.
Mainly due to an addition to
Long-term loans 3,028,666,590.94 826,780,252.78 266.32 long-term borrowings during the
current period.
Mainly due to change of
exchange differences on
Other comprehensive
37,371,610.95 5,387,545.97 593.67 translation of statements as a
income
result of fluctuation in exchange
rate.
January to January to Change in
Statement of Income September for September for proportion Main Reason
2022 2021 （%）
Mainly due to the deposit interest
Financial expenses -330,371,807.68 -43,302,001.92 N/A during the current period is
higher than last period and the
4 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
exchange gains arising from
fluctuation in exchange rate.
Primarily due to a decrease in
dividend for the current period,
Income from
together with fluctuation in
investments (loss is 48,386,584.36 69,260,277.50 -30.14
exchange rate and losses from
indicated by“-”)
settlement of the forward foreign
exchange contract business.
Gains from changes in Primarily due to fluctuations in
fair values (loss is -86,989,533.83 -18,014,545.96 N/A market value of the securities
indicated by“-”) investment held.
Primarily due to the impairment
Impairment loss of
provision for inventories for the
assets (loss is indicated -142,159,872.24 -35,798,711.62 N/A
current period is higher than last
by“-”)
period.
Gains from disposal of Mainly due to gains from transfer
assets (loss is indicated 1,121,679.66 18,357,859.21 -93.89 of land use rights during last
by“-”) period.
January to January to Change in
Cash Flow Statement September for September for proportion Main Reason
2022 2021 （%）
Mainly due to an increase of cash
Net cash flow from
2,608,992,532.97 1,621,169,704.58 60.93 collections of sales revenues for
operating activities
the current period.
Mainly due to the combination of
Net cash flow from cash collection through selling
-886,929,197.44 -1,509,334,937.50 N/A
investing activities equity and the additional
investment for last period.
Mainly due to the further
Net cash flow from borrowings and capital raised
873,841,344.96 -1,783,771,890.06 N/A
financing activities (issuance of GDRs) for the
current period.
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
Total number of holders of ordinary Total number of holders of preferred
shares as of the end of the Reporting 96,795 shares with restored voting rights as of 0
Period the end of the Reporting Period (if any)
Shareholdings of the top 10 shareholders
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholder
shareholder shares held (%) with selling
restrictions Share
Number
status
Domestic non-
Shenzhen Baiyeyuan Investment Co.,
state-owned 878,272,753 45.56 0 Pledge 95,679,725
Ltd. (深圳市百业源投资有限公司)
entity
Hong Kong Securities Clearing Company
Unknown 130,019,561 6.74 0 Unknown
Limited
Citibank, National Association Unknown 63,825,000 3.31 0 Unknown
5 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Might Seasons Limited Foreign entity 57,487,434 2.98 0 Unknown
Huaxia Life Insurance Co., Ltd. - Own
Unknown 9,275,718 0.48 0 Unknown
fund
Domestic
He Zhong 7,800,024 0.40 0 Unknown
natural person
Abu Dhabi Investment Authority (阿布达
Foreign entity 6,334,742 0.33 0 Unknown
比投资局)
Joincare Pharmaceutical Group Industry
Co., Ltd. — the Second Phase Ownership
Scheme under Medium to Long-term
Business Partner Share Ownership Others 6,275,372 0.33 0 -
Scheme (健康元药业集团股份有限公司
－中长期事业合伙人持股计划之第二
期持股计划)
16011 portfolio of basic endowment
Unknown 5,867,634 0.30 0 Unknown
insurance fund
Agricultural Bank of China Limited - CSI
500 Exchange Traded Index Securities Unknown 5,480,994 0.28 0 Unknown
Investment Fund
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable shares held Class and number of shares
Name of shareholder
without selling restrictions Class of shares Number
Ordinary shares
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
878,272,753 denominated in 878,272,753
投资有限公司) Renminbi
Ordinary shares
Hong Kong Securities Clearing Company Limited 130,019,561 denominated in 130,019,561
Renminbi
Ordinary shares
Citibank, National Association 63,825,000 denominated in 63,825,000
Renminbi
Ordinary shares
Might Seasons Limited 57,487,434 denominated in 57,487,434
Renminbi
Ordinary shares
Huaxia Life Insurance Co., Ltd. - Own fund 9,275,718 denominated in 9,275,718
Renminbi
Ordinary shares
He Zhong 7,800,024 denominated in 7,800,024
Renminbi
Ordinary shares
Abu Dhabi Investment Authority (阿布达比投资局) 6,334,742 denominated in 6,334,742
Renminbi
Joincare Pharmaceutical Group Industry Co., Ltd. — the
Second Phase Ownership Scheme under Medium to Long- Ordinary shares
term Business Partner Share Ownership Scheme (健康元药 6,275,372 denominated in 6,275,372
业集团股份有限公司－中长期事业合伙人持股计划之第 Renminbi
二期持股计划)
Ordinary shares
16011 portfolio of basic endowment insurance fund 5,867,634 denominated in 5,867,634
Renminbi
Ordinary shares
Agricultural Bank of China Limited - CSI 500 Exchange
5,480,994 denominated in 5,480,994
Traded Index Securities Investment Fund
Renminbi
There was no connection or acting-in-concert relationship between
Description of connection or acting-in-concert relationship Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
of the above shareholders Company, and other shareholders; whether there is connection or acting-in-
concert relationship among other shareholders is unknown
6 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
As of the end of the Reporting Period, the number of the shares lent from
Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
Description of the participation of the top 10 shareholders
Company, through participation in refinancing is 17,380,900, without any
and the top 10 shareholders without selling restrictions in
transfer of ownership.
margin financing and securities lending and refinancing
He Zhong, a shareholder, holds a total of 7,800,024 shares of the Company,
business (if any)
including 800,000 shares held through ordinary securities accounts and
7,000,024 shares held through credit securities accounts.
As of the end of the Reporting Period, the special repurchase account of the
Description of the special repurchase account among the Company (special securities repurchase account of Joincare Pharmaceutical
top 10 shareholders Group Industry Co., Ltd.) owned 17,459,813 shares in total, accounting for
0.91%.
Note: Citibank, National Association is the depositary of the Company’s GDRs, the corresponding domestic
basic A Shares of GDRs shall registered under its name according to the laws; the GDRs issued by the Company
shall be not converted into A Shares from 26 September 2022 (Switzerland Time) to 23 January 2023
(Switzerland Time).
III. OTHER REMINDERS
Other important information that needs to be brought to the attention of investors regarding the
Company’s operations during the Reporting Period
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
7 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Consolidated Balance Sheet
30 September 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
Item 30 September 2022 31 December 2021
Current assets:
Monetary funds 14,574,355,344.50 11,729,230,390.98
Financial assets held for trading 121,394,233.59 184,638,344.31
Bill receivable 1,761,732,574.61 1,977,286,022.02
Accounts receivable 3,348,701,858.06 2,853,655,551.54
Receivables financing
Prepayments 390,858,423.43 369,232,546.29
Other receivables 51,182,462.61 88,053,825.12
In which: Interests receivable 365,873.64
Dividends receivable
Inventories 2,293,286,563.09 2,078,944,387.68
Contract assets
Held-for-sale assets
Non-current assets due within one year 38,498.84 317,381.23
Other current assets 28,941,853.23 83,986,214.37
Total current assets 22,570,491,811.96 19,365,344,663.54
Non-current assets:
Debt investment
Other debt investment
Long-term receivables 82,574.69 266,904.13
Long-term equity investment 1,445,516,030.89 1,419,349,454.84
Other equity instrument investment 1,202,246,220.39 1,408,882,377.42
Other non-current financial assets
Investment properties 6,191,475.43 6,191,475.43
Fixed assets 5,031,567,135.95 4,839,005,169.81
Construction in progress 914,020,725.38 742,998,743.75
Productive biological assets
Oil & gas assets
Right-of-use assets 41,072,299.34 46,774,759.69
Intangible assets 507,221,484.83 456,782,094.80
Development expenses 803,845,060.85 786,993,435.71
Goodwill 614,468,698.73 614,468,698.73
Long-term prepaid expenses 248,031,970.13 200,715,740.93
Deferred income tax assets 599,351,023.48 552,542,866.71
Other non-current assets 729,588,852.49 663,584,003.80
Total non-current assets 12,143,203,552.58 11,738,555,725.75
Total assets 34,713,695,364.54 31,103,900,389.29
Current liabilities:
Short-term loans 2,355,133,620.36 2,518,484,835.09
Financial liabilities held for trading 23,888,725.35 143,302.24
Notes payable 1,704,031,516.46 1,582,386,767.93
Accounts payable 875,494,946.90 871,553,210.51
Receipts in advance
Contract liabilities 85,390,395.48 234,140,702.29
Payroll payable 422,866,738.80 475,430,823.20
Taxes payable 356,093,489.85 270,618,183.41
8 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Other payables 3,629,808,271.81 3,292,407,989.79
In which: Interests payable
Dividends payable 14,009,877.69 6,951,984.46
Held-for-sale liabilities
Non-current liabilities due within one year 19,385,099.93 91,576,066.33
Other current liabilities 5,977,716.75 15,626,224.29
Total current liabilities 9,478,070,521.69 9,352,368,105.08
Non-current liabilities:
Long-term loans 3,028,666,590.94 826,780,252.78
Bonds payable
Lease liabilities 22,778,162.56 25,071,794.32
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 458,651,827.54 433,543,352.40
Deferred income tax liabilities 191,906,813.07 208,525,905.39
Other non-current liabilities 84,000,000.00 78,000,000.00
Total non-current liabilities 3,786,003,394.11 1,571,921,304.89
Total liabilities 13,264,073,915.80 10,924,289,409.97
Owner's equity (or shareholder's equity):
Paid-in capital 1,927,655,269.00 1,907,727,908.00
Other equity instruments
In which: Preferred shares
Perpetual debts
Capital reserve 2,358,462,480.42 2,265,357,311.92
Less: Treasury shares 222,644,454.50 222,644,454.50
Other comprehensive income 37,371,610.95 5,387,545.97
Special reserve
Surplus reserve 649,438,942.77 640,821,179.08
Undistributed profits 8,150,208,360.92 7,223,644,166.22
Total owner's equity (or shareholder's equity)
12,900,492,209.56 11,820,293,656.69
attributable to the parent company
Minority shareholder's equity 8,549,129,239.18 8,359,317,322.63
Total owner's equity (or shareholder's equity) 21,449,621,448.74 20,179,610,979.32
Total liabilities and owner's equity (or
34,713,695,364.54 31,103,900,389.29
shareholder's equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department: Qiu
Qiu Qingfeng Qingfeng
9 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Consolidated Income Statement
From January to September, 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three
First three quarters
quarters (January
Item (January to
to September) for
September) for 2022
2021
I. Total revenue 13,011,966,738.16 11,933,648,988.85
In which: Operating revenue 13,011,966,738.16 11,933,648,988.85
II. Total operating costs 10,347,452,908.46 9,728,395,382.69
In which: Operating costs 4,590,752,440.39 4,202,628,262.24
Operating tax and surcharges 148,072,490.55 138,588,360.34
Selling expenses 3,893,351,191.76 3,820,420,328.92
Administrative expenses 813,143,493.11 651,003,507.97
R&D expenses 1,232,505,100.33 959,056,925.14
Financial expenses -330,371,807.68 -43,302,001.92
In which: Interest expenses 95,844,022.98 73,581,421.29
Interest income 296,268,948.39 111,786,015.39
Add: Other income 142,661,731.19 177,015,688.29
Income from investments (loss is indicated by“-”) 48,386,584.36 69,260,277.50
In which: Income from investments in associates and
52,468,548.10 11,789,322.81
joint ventures
Gains from derecognition of financial assets at
amortized cost
Gains from net exposure hedges (loss is indicated
by“-”)
Gains from changes in fair values (loss is indicated
-86,989,533.83 -18,014,545.96
by“-”)
Losses of credit impairment (loss is indicated by“-”) -9,508,656.53 -10,549,870.63
Impairment loss of assets (loss is indicated by“-”) -142,159,872.24 -35,798,711.62
Gains from disposal of assets (loss is indicated by“-”) 1,121,679.66 18,357,859.21
III. Operating profit (loss is indicated by“-”) 2,618,025,762.31 2,405,524,302.95
Add: Non-operating income 4,995,275.26 5,662,349.74
Less: Non-operating expenses 13,738,456.89 19,120,502.95
IV. Total profit (loss is indicated by“-”) 2,609,282,580.68 2,392,066,149.74
Less: Income tax expenses 408,012,299.49 316,486,740.44
V. Net profit (loss is indicated by“-”) 2,201,270,281.19 2,075,579,409.30
(I) Classified by business continuity
1. Net profit from ongoing operation (loss is indicated
2,201,270,281.19 2,075,579,409.30
by“-”)
2. Net profit from discontinuing operation (loss is
indicated by“-”)
(II) Classified by ownership
1.Net profit attributable to shareholders of the parent
1,126,561,953.23 1,008,675,184.73
company (loss is indicated by“-”)
2.Profit and loss of minority shareholders (loss is
1,074,708,327.96 1,066,904,224.57
indicated by“-”)
VI. Other comprehensive income, net of tax 80,412,282.94 -177,089,388.22
(I) Other comprehensive income attributable to owners of
31,984,064.97 -90,541,944.15
the parent company, net of tax
1. Other comprehensive income that cannot be
12,029,097.03 -55,197,967.72
reclassified into profit or loss
10 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
(1) Changes from remeasurement of defined benefit
plans
(2) Other comprehensive income that cannot be
1,173,144.60 -3,992,639.64
reclassified into profit or loss under the equity method
(3) Changes in fair value of investments in other equity
10,855,952.43 -51,205,328.08
instruments
(4) Changes in fair value of the enterprise's own credit
risks
2. Other comprehensive income that will be reclassified
19,954,967.94 -35,343,976.43
into profit or loss
(1) Other comprehensive income that can be reclassified
into profit or loss under the equity method
(2) Changes in fair value of other debt investments
(3) Amount of financial assets reclassified into other
comprehensive income
(4) Provision for credit impairment of other debt
investments
(5) Reserve for cash flow hedges
(6) Exchange differences on translation of financial
19,954,967.94 -35,343,976.43
statements denominated in foreign currencies
(7) Others
(II) Other comprehensive income attributable to minority
48,428,217.97 -86,547,444.07
shareholders, net of tax
VII. Total comprehensive income 2,281,682,564.13 1,898,490,021.08
(I) Total comprehensive income attributable to owners of
1,158,546,018.20 918,133,240.58
the parent company
(II) Total comprehensive income attributable to minority
1,123,136,545.93 980,356,780.50
shareholders
VIII. Earnings per share:
(I) Basic earnings per share (RMB/share) 0.5983 0.5154
(II) Diluted earnings per share (RMB/share) 0.5971 0.5142
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department: Qiu
Qiu Qingfeng Qingfeng
11 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
Consolidated Cash Flow Statement
From January to September, 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three First three
quarters quarters
Item (January to (January to
September) for September) for
2022 2021
I. Cash flow from operating activities:
Cash received from sales of goods and rendering of services 13,705,807,329.89 11,899,181,183.24
Tax refunds 219,263,256.92 117,304,422.29
Other cash received related to operating activities 536,180,845.96 357,722,261.48
Subtotal of cash inflow from operating activities 14,461,251,432.77 12,374,207,867.01
Cash paid for goods and services 4,180,212,054.68 3,161,363,236.72
Cash paid to and on behalf of employees 1,797,221,409.89 1,546,737,299.97
Taxes paid 1,293,188,165.95 1,263,867,720.70
Other cash paid related to operating activities 4,581,637,269.28 4,781,069,905.04
Subtotal of cash outflow in operating activities 11,852,258,899.80 10,753,038,162.43
Net cash flow from operating activities 2,608,992,532.97 1,621,169,704.58
II. Cash flow from investing activities:
Cash received from withdrawal of investment 216,970,980.42 110,302,936.39
Cash received from investment income 121,905,782.77 93,348,249.99
Net cash received from disposal of fixed assets, intangible
1,307,684.20 8,684,509.74
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
3,311,220.53
business units
Other cash received related to investing activities 13,356,765.87 14,765,008.34
Subtotal of cash inflow from investing activities 353,541,213.26 230,411,924.99
Cash paid for purchase and construction of fixed assets,
975,980,046.68 960,679,392.16
intangible assets and other long-term assets
Cash paid for investment 37,995,968.80 774,000,000.00
Net cash paid for acquisition of subsidiaries and other
business units
Other cash paid related to investing activities 226,494,395.22 5,067,470.33
Subtotal of cash outflow in investing activities 1,240,470,410.70 1,739,746,862.49
Net cash flow from investing activities -886,929,197.44 -1,509,334,937.50
III. Cash flow from financing activities:
Cash received from absorption of investments 719,365,346.09 521,836,124.79
In which: Cash received by subsidiaries from investments of
324,225,000.00
minority shareholders
Borrowings received 5,297,022,796.00 2,354,753,015.63
Other cash received related to financing activities 303,958,487.50 34,430,100.74
Subtotal of cash inflow from financing activities 6,320,346,629.59 2,911,019,241.16
Cash repayment 3,504,080,892.47 2,282,684,146.53
Cash paid for dividend and profit distribution or interest
1,314,118,888.43 1,211,553,686.47
payment
In which: Dividends and profit paid by subsidiaries to
1,314,118,888.43 846,741,767.14
minority shareholders
Other cash paid related to financing activities 628,305,503.73 1,200,553,298.22
Subtotal of cash outflow in financing activities 5,446,505,284.63 4,694,791,131.22
Net cash flow from financing activities 873,841,344.96 -1,783,771,890.06
12 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 Third Quarterly Report
IV. Influence of exchange rate fluctuations on cash and cash
227,244,304.84 -20,822,588.77
equivalents
V. Net increase in cash and cash equivalents 2,823,148,985.32 -1,692,759,711.75
Add: Opening balance of cash and cash equivalents 11,697,518,141.18 12,122,781,311.49
VI. Closing balance of cash and cash equivalents 14,520,667,126.50 10,430,021,599.74
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department: Qiu
Qiu Qingfeng Qingfeng
Implementation of, such as new accounting standards or interpretations of standards, for the first time
from 2022 involves adjustments to the financial statements at the beginning of the year of first-time
implementation
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
26 October, 2022
13 / 13
